MRgFUS.

Summary

This study is looking for healthy controls to participate in an MRI scan. Healthy controls will be chosen based on age and sex to match a group of patients already recruited for the study. This study requires volunteers to participate in two MRI scans that will be conducted at the Foothills Hospital location. The first scan will be after study enrollment and the second will be a follow-up scan a year later.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 90

Accepts healthy participants: Yes

Inclusion criteria:

1. Adults age 18 years or older who report being in good health.
2. Subjects on stable antidepressant medications for at least 3 months may be enrolled into this study (i.e., no change in medication drug or dosage for 3 months).

Exclusion criteria:

1. History of neurological disease.
2. Family history of movement disorder.
3. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

Courtney Collins, Research Assistant

Principal investigator:

Zelma Kiss

Clinical trial:

No

REB-ID:

REB17-0649